Details of the Drug Combination

General Information of Drug Combination (ID: DCVFR6W)

Drug Combination Name
AG-881 Rotenone
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs AG-881   DMIE1WY Rotenone   DMV04ES
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 23.951
Bliss Independence Score: 28.774
Loewe Additivity Score: 0.786
LHighest Single Agent (HSA) Score: 2.866

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of AG-881
Disease Entry ICD 11 Status REF
Glioma 2A00.0 Phase 3 [2]
Acute myeloid leukaemia 2A60 Phase 1 [3]
AG-881 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Isocitrate dehydrogenase (IDH) TTDTWV0 IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Rotenone
Disease Entry ICD 11 Status REF
Piscicide N.A. Approved [4]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT04164901) Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015